Navigation Links
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Date:1/11/2010

ld senior clinical positions at XOMA, including vice president of clinical science. In addition to overseeing clinical development programs at XOMA, Dr. Garovoy was responsible for managing clinical collaborations with external partners.

"Bavituximab is a promising new approach with broad potential for the treatment of solid cancers and other diseases," said Dr. Garovoy. "Based on the encouraging results seen in early clinical trials, I welcome the opportunity to collaborate with clinical researchers to establish the investigator-sponsored studies that will enhance our understanding of the clinical potential of this exciting new agent."

Dr. Garovoy has authored over 200 medical publications and holds two patents. He held teaching positions as a faculty member at Harvard Medical School and more recently as a Professor of Surgery and Medicine at the University of California, San Francisco. Dr. Garovoy received a BA degree from New York University and an MD degree with honors from the State University of New York Downstate Medical Center. He completed a post-graduate fellowship in Immunology and Transplantation at Harvard Medical School.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
2. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
3. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
8. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
9. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
10. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
11. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... WASHINGTON , June 30, 2015  NASA astronaut ... launch next month on his first mission to the ... interviews from 8 to 9 a.m. EDT Tuesday, July 7. ... Center in Star City, Russia . The ... on NASA Television highlighting his mission training. To ...
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender offer ... stock). On June 29, 2015, the last trading day prior to the commencement of ... was $2.29 per share. , The tender offer will expire on July 28, 2015 ...
Breaking Biology Technology:NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... WA, Jan. 28 /PRNewswire-FirstCall/ - Oncothyreon Inc. (the,"Company") ... specializing,in the development of innovative therapeutic products for ... the Company,s clinical development plans,and corporate objectives for ... targeted small molecules with the potential to,improve the ...
... - European Patent Office Grants Patent for Treatment of ... the field of human gene therapy, today,announced that the ... patent for the treatment of Non-Alcoholic Steatotic Hepatitis,(NASH) with ... pending with,the U.S. Patent and Trademark Office., The ...
... 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, 107024, 107064, ... ... DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the voluntary recall ... vials. The company,began recalling the lots on January 17, 2008 as a ...
Cached Biology Technology:Oncothyreon highlights corporate and clinical objectives for 2008 2Oncothyreon highlights corporate and clinical objectives for 2008 3Oncothyreon highlights corporate and clinical objectives for 2008 4Oncothyreon highlights corporate and clinical objectives for 2008 5AMT's Lead Product Poised to Address Major Liver Disease 2AMT's Lead Product Poised to Address Major Liver Disease 3Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... 23, 2015   Valencell, a leader ... of a recent study that illustrates its PerformTek ... during activity. In a study conducted at Valencell,s ... with the Apple Watch against a chest strap ... during activity. The study demonstrated that Valencell,s biometric ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... research about pollution in the Ganges River has reached ... MSU scientists who study the 1,500-mile river. "It,s ... by a government institute in India and being presented ... in microbiology. "Lots of things get done judicially in ...
... feed on seaweed could help in the disposal of ... study by researchers in China and Japan. The discovery ... Inderscience publication. Shinichi Nagata of the Environmental Biochemistry ... Shimane University and at Nankai University, China, explain that ...
... Men whose prostate cancer screenings show high grade prostatic ... between diagnoses they are told prostate cancer has ... advised to undergo repeated needle biopsies as a precaution. ... of distinguishing between HG-PIN lesions destined to become cancerous ...
Cached Biology News:Montana State University research reaches Supreme Court of India 2Wakame waste 2Biomarker predicts malignancy potential of HG-PIN lesions in the prostate 2Biomarker predicts malignancy potential of HG-PIN lesions in the prostate 3
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: